TIDMHIK
RNS Number : 5097L
Hikma Pharmaceuticals Plc
30 April 2020
Hikma Pharmaceuticals PLC
Voting Results of 2020 Annual General Meeting
LONDON, 30 April 2020 Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated
Ba1/stable Moody's and BB+/positive S&P) announces its Annual
General Meeting ("AGM"), held at 22 Regent Road, Surbiton KT5 8NL
on 30 April 2020 commenced at 10:00 am. All resolutions were duly
passed by shareholders by way of a poll. Resolutions 1 to 18 were
passed as ordinary resolutions and Resolutions 19 to 22 were passed
as special resolutions.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the National Storage Mechanism
and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 26 February 2020) is set out below. The number of
Ordinary Shares in issue on 30 April 2020 was 242,543,355.
Resolution Votes For % Votes Against % Total Cast Withheld
1. To receive the
2019 report and
accounts 201,698,273 99.99 57 0.01 201,698,330 1,120,694
------------ ------ -------------- ------ ------------ ----------
2. To approve a
final dividend of
30 cents per share 202,811,365 99.99 6,764 0.01 202,818,129 895
------------ ------ -------------- ------ ------------ ----------
3. To re-appoint
PricewaterhouseCoopers
LLP as auditors 202,808,789 99.99 8,990 0.01 202,817,779 1,245
------------ ------ -------------- ------ ------------ ----------
4. To authorise
the Audit Committee
to determine the
auditors' remuneration 202,814,187 99.99 3,664 0.01 202,817,851 1,173
------------ ------ -------------- ------ ------------ ----------
5. To elect Cynthia
Schwalm as a director 201,548,814 99.37 1,268,304 0.63 202,817,118 1,906
------------ ------ -------------- ------ ------------ ----------
6. To re-elect
Said Darwazah as
a director 196,190,726 96.77 6,538,997 3.23 202,729,723 89,301
------------ ------ -------------- ------ ------------ ----------
7. To re-elect
Siggi Olafsson as
a director 200,700,552 98.96 2,117,034 1.04 202,817,586 1,438
------------ ------ -------------- ------ ------------ ----------
8. To re-elect
Mazen Darwazah as
a director 197,442,264 97.35 5,375,322 2.65 202,817,586 1,438
------------ ------ -------------- ------ ------------ ----------
9. To re-elect
Robert Pickering
as a director 196,820,454 97.04 5,996,664 2.96 202,817,118 1,906
------------ ------ -------------- ------ ------------ ----------
10. To re-elect
Ali Al-Husry as
a director 199,416,313 98.32 3,401,273 1.68 202,817,586 1,438
------------ ------ -------------- ------ ------------ ----------
11. To re-elect
Patrick Butler as
a director 199,744,398 98.48 3,073,188 1.52 202,817,586 1,438
------------ ------ -------------- ------ ------------ ----------
12. To re-elect
Dr. Pamela Kirby
as a director 195,639,660 96.46 7,177,925 3.54 202,817,585 1,438
------------ ------ -------------- ------ ------------ ----------
13 . To re-elect
Dr. Jochen Gann
as a director 199,704,876 98.47 3,112,710 1.53 202,817,586 1,438
------------ ------ -------------- ------ ------------ ----------
14 . To re-elect
John Castellani
as a director 199,425,273 98.80 2,426,100 1.20 201,851,373 967,651
------------ ------ -------------- ------ ------------ ----------
15 . To re-elect
Nina Henderson as
a director 200,433,121 98.82 2,384,465 1.18 202,817,586 1,438
------------ ------ -------------- ------ ------------ ----------
16. To approve
the remuneration
policy 190,931,576 95.50 8,992,802 4.50 199,924,378 2,894,646
------------ ------ -------------- ------ ------------ ----------
17. To approve
the remuneration
report for the year
ended 31 December
2019 190,252,825 95.16 9,671,582 4.84 199,924,407 2,894,616
------------ ------ -------------- ------ ------------ ----------
18. Authority to
allot shares 177,783,521 87.66 25,033,088 12.34 202,816,609 2,415
------------ ------ -------------- ------ ------------ ----------
19 . To dis-apply
pre-emption rights
for general purposes 202,778,888 99.98 37,721 0.02 202,816,609 2,415
------------ ------ -------------- ------ ------------ ----------
20. To dis-apply
pre-emption rights
for an acquisition
or other capital
investment 201,813,423 99.51 1,003,156 0.49 202,816,579 2,445
------------ ------ -------------- ------ ------------ ----------
21. To authorise
the Company to purchase
its own shares 201,634,579 99.44 1,133,921 0.56 202,768,500 50,524
------------ ------ -------------- ------ ------------ ----------
22. To authorise
the Company to hold
general meetings
on no less than
14 clear days' notice 197,970,909 97.61 4,846,842 2.39 202,817,751 1,273
------------ ------ -------------- ------ ------------ ----------
Declaration of final dividend
The dividend of 30 cents per share will be paid on 7 May 2020 to
shareholders on the register on 20 March 2020. Shareholders who are
not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $1.238806 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at circa 1JD to
$1.41.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2670
Susan Ringdal
EVP, Strategic Planning and Global Affairs +44 20 7399 2670
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit: www.hikma.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGSDIFSSESSEIL
(END) Dow Jones Newswires
April 30, 2020 07:00 ET (11:00 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mag 2023 a Mag 2024
